Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

d, one as a result of pneumonia and one of an unknown cause. Four patients discontinued treatment due to adverse events. Two of these discontinuations were due to cardiac events (myocardial infarction in one patient and arrhythmia, diminished cardiac output, and hypotension in the other patient).

The incidence of hypomagnesemia (both overall and severe [NCI CTC Grades 3 & 4]) was increased in patients receiving ERBITUX alone or in combination with chemotherapy as compared to those receiving best supportive care or chemotherapy alone based on ongoing, controlled clinical trials in 244 patients. Approximately one-half of these patients receiving ERBITUX experienced hypomagnesemia and 10-15% experienced severe hypomagnesemia. Electrolyte repletion was necessary in some patients and in severe cases, intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy.

The most serious adverse reactions associated with ERBITUX in combination with radiation therapy in 208 patients with head and neck cancer were infusion reaction (3%), cardiopulmonary arrest (2%), dermatologic toxicity (2.5%), mucositis (6%), radiation dermatitis (3%), confusion (2%), and diarrhea (2%).

The most serious adverse reactions associated with ERBITUX in mCRC clinical trials (N=774) were infusion reaction (3%), dermatologic toxicity (1%), interstitial lung disease (0.4%), fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX with irinotecan, 2% in patients receiving ERBITUX as a single agent) and diarrhea (6% in patients receiving ERBITUX with irinotecan, 0.2% in patients receiving ERBITUX as a single agent).

The overall incidence of late radiation toxicities (any grade) was higher with ERBITUX in combination with radiation therapy c
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/22/2014)... -- Children,s National Health System has announced an ... p.m. EDT for its "Make Your Medical Device ... strong interest from inventors.  Two top ... the winning presentations at the Sheikh Zayed Institute Second ... National in October. For competition details,  click here ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
(Date:9/22/2014)... , Sept. 22, 2014 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products, is ... Biomedical Inc. ("Thunderbird"), has signed a definitive lease agreement ... , BC.  The facility has 28,966 square feet ... 14,500 square feet of mezzanine space for a total ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3
... N.J., July 11, 2011 MonoSol Rx, a ... PharmFilm® technology platform, in collaboration with APR Applied ... that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble ... partners.  The Company made the strategic decision to ...
... YORK, July 11, 2011 Reportlinker.com announces ... available in its catalogue: ... approval brings lessons and hope to market ... To order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... months and older be vaccinated for the upcoming flu season. ... recommendations to advise that the youngest kids should have two ... wants parents of children aged 2 to 8 to consider ... flu shot if it,s readily available. "It,s important to ...
(Date:9/22/2014)... have found that an anticonvulsant drug may help in ... dozens of antibiotics target what bacteria do, their study ... are created, and they found there is a way ... as there is growing concern worldwide about how antibiotic ... World Health Organization has declared that antibiotic resistance is ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Quincy ... the United States, promotes National Self-Improvement Month ... that all individuals should have access to self-improvement ... aging. , The demand for products that preserve ... than ever before. For over six years, Quincy ...
(Date:9/22/2014)... 22, 2014 (HealthDay News) -- Scans of young ... to read. This finding could potentially allow doctors ... difficulties early on, preliminary research suggests. "Early ... with dyslexia as well as most neurodevelopmental disorders," ... associate professor of child and adolescent psychiatry at ...
Breaking Medicine News(10 mins):Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... working at the Swiss Institute for Experimental Cancer Research ... discovered that telomeres, the repeated DNA-protein complexes at the ... cell divides, also contain RNA. This discovery, published online ... understanding of how telomeres function, and may provide a ...
... Success of 2007 National IPF Awareness Week on ... Deadly Lung Disease, SAN JOSE, Calif., Oct. ... announced that the success of its fifth,annual National ... 60,members of Congress about the critical need to ...
... Oct. 4 The following statement was issued,today by ... and Janet,Jenner & Suggs, LLC: Out of public ... million,pound recall of potentially E. coli contaminated ground beef ... & SUGGS, LLC.,have established a registry for victims of ...
... Academy of General,Dentistry (AGD) was extremely disappointed by ... Health Insurance Program (SCHIP),reauthorization bill. The SCHIP bill ... included many important and beneficial dental,provisions intended to ... However, President Bush, who had threatened to veto ...
... provide tobacco cessation services for three more years, ... beBetter,Networks, Inc. (beBetter) has been awarded the West ... Health and Human Resources,for the Bureau for Public ... As the original vendor for the Quitline, beBetter ...
... canola,oil for common dietary fats in the U.S. ... and plant omega-3 fats,noted a modeling study published ... the American Dietetic Association (JADA). The study examined ... oils and canola oil-based,margarine for other margarines and ...
Cached Medicine News:Health News:New telomere discovery could help explain why cancer cells never stop dividing 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning 2Health News:Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning 3Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:beBetter Awarded WV Quitline Contract 2Health News:Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2
... Safety Knife with BD Xstar Blade includes ... protects the blade in prodedure and handling. ... on a grind-less process for manufacturing surgical ... sharpness and consistency. The arch style, ...
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
... The BD Safety Knife with BD ... retractable shield that protects the blade in ... technology is based on a grind-less process ... process yields outstanding sharpness and consistency. ...
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
Medicine Products: